Aerie Pharmaceuticals, Inc.
- Jurisdiction
United States - LEI
529900SFXHDHUO324R09 - ISIN
US00771V1089 (AERI )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
5
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
7
/ 7
Profile
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Read full profile
Fundamentals
- Net revenue
€182.48M - Gross margin
89.0% - EBIT
-€19.82M - EBIT margin
-10.9% - Net income
-€31.18M - Net margin
-17.1%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions